



Investigating the role of the centromeric histone variant CENP-A in cancer





**Daniel CB Jeffery - Post-doc
Almouzni Lab - Institut Curie
March 2018**

www.futura-sciences.com

Overexpression of CENP-A and HJURP is observed in a range of aggressive cancers

Is this just a correlation or does CENP-A/HJURP excess give an advantage to cancer cells?



→ CENP-A/HJURP excess (and mislocalization) provides a cancer-specific advantage?

What are the mechanisms behind this apparent CENP-A/HJURP-dependent advantage?


- Compensation by alternative pathways?
- Unusual chromatin: impinging on centromere function / DNA damage response?

Can we exploit this for cancer treatment?

Inducible + reversible overexpression...

Human cell lines with different p53 status

Isogenic cell lines with defective p53



Acknowledgements

ALMOUZNI LAB

Geneviève Almouzni

Delphine Bailly

Ekaterina Boyarchuk

Camille Clément

Anaïs Defontaine

Audrey Forest

Alberto Gatto

Hatem Hmidan

Daniel Jeffery

Christèle Maison

Pierre-Antoine Mauro

Shweta Mendiratta

Guille Orsi

François Piumi



Continued...

Katrina Podsypanina

Jean-Pierre Quivy

Dominique Ray-Gallet

Iva Simeonova

David Sitbon

Julia Torne

Tejas Yadav

Former members:

Monica Naughtin

Dan Filipescu

Nicolas Lacoste



Association
pour la Recherche
sur le Cancer

Thank you! And I encourage you to visit my poster for the rest of the story!